Loading…

Gallbladder cancer: current and future treatment options

Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical eff...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2023-05, Vol.14, p.1183619-1183619
Main Authors: Zhou, Yanzhao, Yuan, Kun, Yang, Yi, Ji, Zemin, Zhou, Dezheng, Ouyang, Jingzhong, Wang, Zhengzheng, Wang, Fuqiang, Liu, Chang, Li, Qingjun, Zhang, Qi, Li, Qiang, Shan, Xiao, Zhou, Jinxue
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823
cites cdi_FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823
container_end_page 1183619
container_issue
container_start_page 1183619
container_title Frontiers in pharmacology
container_volume 14
creator Zhou, Yanzhao
Yuan, Kun
Yang, Yi
Ji, Zemin
Zhou, Dezheng
Ouyang, Jingzhong
Wang, Zhengzheng
Wang, Fuqiang
Liu, Chang
Li, Qingjun
Zhang, Qi
Li, Qiang
Shan, Xiao
Zhou, Jinxue
description Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.
doi_str_mv 10.3389/fphar.2023.1183619
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fd1a6dcb6e1d4979a0512975bac0e77b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_fd1a6dcb6e1d4979a0512975bac0e77b</doaj_id><sourcerecordid>2820970502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823</originalsourceid><addsrcrecordid>eNpVkU1P3DAQQK2qqCDKH-ihypHLLh7b8UcvqEItRULiUs7W2J5AUDbe2kml_nuy7BaBL2PNeJ7Hfox9Ab6W0rqLbvuIZS24kGsAKzW4D-wEtJYrZ0F8fLM_Zme1PvFlSeekVp_YsTSiBQnuhNlrHIYwYEpUmohjpPKtiXMpNE4Njqnp5mku1EyFcNrsknk79Xmsn9lRh0Ols0M8Zfc_f_y--rW6vbu-ufp-u4pKu2llXeAEyrU6mShJthitiQEcdEJFbA13iQcNArmyPDllFagOkWOrKVghT9nNnpsyPvlt6TdY_vmMvX9J5PLgsUx9HMh3CVCnGDRBUs445C0IZ9qAkZMxYWFd7lnbOWwoxeU5BYd30PeVsX_0D_mvBy5g-XS3EM4PhJL_zFQnv-lrpGHAkfJcvbCCO8Nbvhtc7I_Gkmst1L3eA9zvFPoXhX6n0B8ULk1f30742vJfmHwG6f2YYg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2820970502</pqid></control><display><type>article</type><title>Gallbladder cancer: current and future treatment options</title><source>PubMed Central</source><creator>Zhou, Yanzhao ; Yuan, Kun ; Yang, Yi ; Ji, Zemin ; Zhou, Dezheng ; Ouyang, Jingzhong ; Wang, Zhengzheng ; Wang, Fuqiang ; Liu, Chang ; Li, Qingjun ; Zhang, Qi ; Li, Qiang ; Shan, Xiao ; Zhou, Jinxue</creator><creatorcontrib>Zhou, Yanzhao ; Yuan, Kun ; Yang, Yi ; Ji, Zemin ; Zhou, Dezheng ; Ouyang, Jingzhong ; Wang, Zhengzheng ; Wang, Fuqiang ; Liu, Chang ; Li, Qingjun ; Zhang, Qi ; Li, Qiang ; Shan, Xiao ; Zhou, Jinxue</creatorcontrib><description>Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2023.1183619</identifier><identifier>PMID: 37251319</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>adjuvant therapy ; clinical stage ; gallbladder cancer ; immunotherapy ; Pharmacology ; targeted therapy</subject><ispartof>Frontiers in pharmacology, 2023-05, Vol.14, p.1183619-1183619</ispartof><rights>Copyright © 2023 Zhou, Yuan, Yang, Ji, Zhou, Ouyang, Wang, Wang, Liu, Li, Zhang, Li, Shan and Zhou.</rights><rights>Copyright © 2023 Zhou, Yuan, Yang, Ji, Zhou, Ouyang, Wang, Wang, Liu, Li, Zhang, Li, Shan and Zhou. 2023 Zhou, Yuan, Yang, Ji, Zhou, Ouyang, Wang, Wang, Liu, Li, Zhang, Li, Shan and Zhou</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823</citedby><cites>FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213899/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213899/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37251319$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Yanzhao</creatorcontrib><creatorcontrib>Yuan, Kun</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><creatorcontrib>Ji, Zemin</creatorcontrib><creatorcontrib>Zhou, Dezheng</creatorcontrib><creatorcontrib>Ouyang, Jingzhong</creatorcontrib><creatorcontrib>Wang, Zhengzheng</creatorcontrib><creatorcontrib>Wang, Fuqiang</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Li, Qingjun</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Shan, Xiao</creatorcontrib><creatorcontrib>Zhou, Jinxue</creatorcontrib><title>Gallbladder cancer: current and future treatment options</title><title>Frontiers in pharmacology</title><addtitle>Front Pharmacol</addtitle><description>Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.</description><subject>adjuvant therapy</subject><subject>clinical stage</subject><subject>gallbladder cancer</subject><subject>immunotherapy</subject><subject>Pharmacology</subject><subject>targeted therapy</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1P3DAQQK2qqCDKH-ihypHLLh7b8UcvqEItRULiUs7W2J5AUDbe2kml_nuy7BaBL2PNeJ7Hfox9Ab6W0rqLbvuIZS24kGsAKzW4D-wEtJYrZ0F8fLM_Zme1PvFlSeekVp_YsTSiBQnuhNlrHIYwYEpUmohjpPKtiXMpNE4Njqnp5mku1EyFcNrsknk79Xmsn9lRh0Ols0M8Zfc_f_y--rW6vbu-ufp-u4pKu2llXeAEyrU6mShJthitiQEcdEJFbA13iQcNArmyPDllFagOkWOrKVghT9nNnpsyPvlt6TdY_vmMvX9J5PLgsUx9HMh3CVCnGDRBUs445C0IZ9qAkZMxYWFd7lnbOWwoxeU5BYd30PeVsX_0D_mvBy5g-XS3EM4PhJL_zFQnv-lrpGHAkfJcvbCCO8Nbvhtc7I_Gkmst1L3eA9zvFPoXhX6n0B8ULk1f30742vJfmHwG6f2YYg</recordid><startdate>20230511</startdate><enddate>20230511</enddate><creator>Zhou, Yanzhao</creator><creator>Yuan, Kun</creator><creator>Yang, Yi</creator><creator>Ji, Zemin</creator><creator>Zhou, Dezheng</creator><creator>Ouyang, Jingzhong</creator><creator>Wang, Zhengzheng</creator><creator>Wang, Fuqiang</creator><creator>Liu, Chang</creator><creator>Li, Qingjun</creator><creator>Zhang, Qi</creator><creator>Li, Qiang</creator><creator>Shan, Xiao</creator><creator>Zhou, Jinxue</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230511</creationdate><title>Gallbladder cancer: current and future treatment options</title><author>Zhou, Yanzhao ; Yuan, Kun ; Yang, Yi ; Ji, Zemin ; Zhou, Dezheng ; Ouyang, Jingzhong ; Wang, Zhengzheng ; Wang, Fuqiang ; Liu, Chang ; Li, Qingjun ; Zhang, Qi ; Li, Qiang ; Shan, Xiao ; Zhou, Jinxue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>adjuvant therapy</topic><topic>clinical stage</topic><topic>gallbladder cancer</topic><topic>immunotherapy</topic><topic>Pharmacology</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Yanzhao</creatorcontrib><creatorcontrib>Yuan, Kun</creatorcontrib><creatorcontrib>Yang, Yi</creatorcontrib><creatorcontrib>Ji, Zemin</creatorcontrib><creatorcontrib>Zhou, Dezheng</creatorcontrib><creatorcontrib>Ouyang, Jingzhong</creatorcontrib><creatorcontrib>Wang, Zhengzheng</creatorcontrib><creatorcontrib>Wang, Fuqiang</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Li, Qingjun</creatorcontrib><creatorcontrib>Zhang, Qi</creatorcontrib><creatorcontrib>Li, Qiang</creatorcontrib><creatorcontrib>Shan, Xiao</creatorcontrib><creatorcontrib>Zhou, Jinxue</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Yanzhao</au><au>Yuan, Kun</au><au>Yang, Yi</au><au>Ji, Zemin</au><au>Zhou, Dezheng</au><au>Ouyang, Jingzhong</au><au>Wang, Zhengzheng</au><au>Wang, Fuqiang</au><au>Liu, Chang</au><au>Li, Qingjun</au><au>Zhang, Qi</au><au>Li, Qiang</au><au>Shan, Xiao</au><au>Zhou, Jinxue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gallbladder cancer: current and future treatment options</atitle><jtitle>Frontiers in pharmacology</jtitle><addtitle>Front Pharmacol</addtitle><date>2023-05-11</date><risdate>2023</risdate><volume>14</volume><spage>1183619</spage><epage>1183619</epage><pages>1183619-1183619</pages><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Surgery remains the preferred treatment option for early-stage gallbladder cancer (GBC). According to the anatomical position of the primary tumor, accurate preoperative stage and strict control of surgical indications, appropriate surgical strategies are selected to achieve the optimal surgical effect. However, most patients have already been at the locally advanced stage or the tumor has metastasized at the initial diagnosis. The postoperative recurrence rate and 5-year survival rate remain unsatisfactory even after radical resection for gallbladder cancer. Hence, there is an urgent need for more treatment options, such as neoadjuvant therapy, postoperative adjuvant therapy and first-line and second-line treatments of local progression and metastasis, in the whole-course treatment management of gallbladder cancer patients. In recent years, the application of molecular targeted drugs and immunotherapy has brought greater hope and broader prospects for the treatment of gallbladder cancer, but their effects in improving the prognosis of patients still lack sufficient evidence-based medicine evidence, so many problems should be addressed by further research. Based on the latest progress in gallbladder cancer research, this review systematically analyzes the treatment trends of gallbladder cancer.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37251319</pmid><doi>10.3389/fphar.2023.1183619</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2023-05, Vol.14, p.1183619-1183619
issn 1663-9812
1663-9812
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_fd1a6dcb6e1d4979a0512975bac0e77b
source PubMed Central
subjects adjuvant therapy
clinical stage
gallbladder cancer
immunotherapy
Pharmacology
targeted therapy
title Gallbladder cancer: current and future treatment options
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gallbladder%20cancer:%20current%20and%20future%20treatment%20options&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Zhou,%20Yanzhao&rft.date=2023-05-11&rft.volume=14&rft.spage=1183619&rft.epage=1183619&rft.pages=1183619-1183619&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2023.1183619&rft_dat=%3Cproquest_doaj_%3E2820970502%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-89b0e14956d7c3e35ac87cb191f24ca5709d0b612a0480d948414faa0a56eb823%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2820970502&rft_id=info:pmid/37251319&rfr_iscdi=true